Back to Results
First PageMeta Content
Pharmaceuticals policy / Orphan Drug Act / Rare disease / Health / Orphanet / Erik Tambuyzer / Pharmacology / Genzyme / Darbepoetin alfa / Medicine / Drug discovery / Orphan drug


History and Commitment from industry in the field of rare diseases and orphan drugs Dr. Erik Tambuyzer Senior Vice-President, Public Policy, Genzyme
Add to Reading List

Document Date: 2010-09-20 11:12:19

Open Document

File Size: 782,59 KB

Share Result on Facebook

Company

Genzyme / /

Continent

Australia / Europe / /

Country

Japan / United States / /

IndustryTerm

healthcare legislation / /

MedicalCondition

frequent rare diseases / rare diseases / diseases / disease / rare disease / /

Organization

office of Health Economics / Joint EBE-EuropaBio Task Force on Rare Diseases / European Union / European Parliament / /

Person

Erik Tambuyzer / /

Position

Chair / Vice-President / Public Policy / /

Product

Celebrex / Pegasys / Soliris / Zoloft / Fosamax / Plavix / Singulair / Lipitor / Nexium / Avastin / Tracleer / Gleevec / Erbitux / Aranesp / Tysabri / Flolan / Elaprase / /

ProgrammingLanguage

EC / /

PublishedMedium

Health Economics / /

SocialTag